Different roles for caveolin-1 in the development of non-small cell lung cancer versus small cell lung cancer

Cancer Research

Volumn 64, Issue 12, 2004, Pages 4277-4285

  Sunaga, Noriaki ^a,c   Miyajima, Kuniharu ^a   Suzuki, Makoto ^a   Sato, Mitsuo ^a   White, Michael A ^a   Ramirez, Ruben D ^a   Shay, Jerry W ^a   Gazdar, Adi F ^a   Minna, John D ^a,b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c GUNMA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; CAVEOLIN 1; FOCAL ADHESION KINASE; SMALL INTERFERING RNA;

ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CAV1 GENE; CAVEOLA; CELL CULTURE; CELL PROLIFERATION; CELL TRANSPORT; COLONY FORMATION; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; GENE EXPRESSION; HUMAN; HUMAN CELL; LUNG CARCINOGENESIS; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; METHYLATION; NUCLEOTIDE SEQUENCE; ONCOGENE; PRIORITY JOURNAL; SUSPENSION CELL CULTURE; TUMOR SUPPRESSOR GENE;

CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SMALL CELL; CAVEOLIN 1; CAVEOLINS; CELL DIVISION; CELL LINE, TUMOR; CODON; DNA METHYLATION; DOWN-REGULATION; FOCAL ADHESION KINASE 1; FOCAL ADHESION PROTEIN-TYROSINE KINASES; GTP PHOSPHOHYDROLASES; HUMANS; LUNG NEOPLASMS; MUTATION; PHOSPHORYLATION; PROMOTER REGIONS (GENETICS); PROTEIN-TYROSINE KINASES; RAL GTP-BINDING PROTEINS; RNA INTERFERENCE; RNA, SMALL INTERFERING; TRANSFECTION;

EID: 3042569629     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-03-3941     Document Type: Article

References (56)

1. Anderson RG, Jacobson K. A role for lipid shells in targeting proteins to caveolae, rafts, and other lipid domains. Science (Wash DC) 2002;296:1821-5.
2. Severs NJ. Caveolae: static inpocketings of the plasma membrane, dynamic vesicles or plain artifact? J Cell Sci 1988;90(Pt 3):341-8.
3. Galbiati F, Razani B, Lisanti MP. Emerging themes in lipid rafts and caveolae. Cell 2001;106:403-11.
4. Okamoto T, Schlegel A, Scherer PE, Lisanti MP. Caveolins, a family of scaffolding proteins for organizing "preassembled signaling complexes" at the plasma membrane. J Biol Chem 1998;273:5419-22.
5. Liu P, Rudick M, Anderson RG. Multiple functions of caveolin-1. J Biol Chem 2002;277:41295-8.
6. Drab M, Verkade P, Elger M, et al. Loss of caveolae, vascular dysfunction, and pulmonary defects in caveolin-1 gene-disrupted mice. Science (Wash DC) 2001;293:2449-52.
7. Razani B, Engelman JA, Wang XB, et al. Caveolin-1 null mice are viable but show evidence of hyperproliferative and vascular abnormalities. J Biol Chem 2001;276:38121-38.
8. Razani B, Altschuler Y, Zhu L, Pestell RG, Mostov KE, Lisanti MP. Caveolin-1 expression is down-regulated in cells transformed by the human papilloma virus in a p53-dependent manner. Replacement of caveolin-I expression suppresses HPV-mediated cell transformation. Biochemistry 2000;39:13916-24.
9. Wiechen K, Diatchenko L, Agoulnik A, et al. Caveolin-1 is down-regulated in human ovarian carcinoma and acts as a candidate tumor suppressor gene. Am J Pathol 2001;159:1635-43.
10. Heighway J, Knapp T, Boyce L, et al. Expression profiling of primary non-small cell lung cancer for target identification. Oncogene 2002;21:7749-63.
11. Wikman H, Kettunen E, Seppanen JK, et al. Identification of differentially expressed genes in pulmonary adenocarcinoma by using cDNA array. Oncogene 2002;21:5804-13.
12. Bender FC, Reymond MA, Bron C, Quest AF. Caveolin-1 levels are down-regulated in human colon tumors, and ectopic expression of caveolin-1 in colon carcinoma cell lines reduces cell tumorigenicity. Cancer Res 2000;60:5870-8.
13. Racine C, Belanger M, Hirabayashi H, Boucher M, Chakir J, Couet J. Reduction of caveolin 1 gene expression in lung carcinoma cell lines. Biochem Biophys Res Commun 1999;255:580-6.
14. Galbiati F, Volonte D, Engelman JA, et al. Targeted downregulation of caveolin-1 is sufficient to drive cell transformation and hyperactivate the p42/44 MAP kinase cascade. EMBO J 1998;17:6633-48.
15. Koleske AJ, Baltimore D, Lisanti MP. Reduction of caveolin and caveolae in oncogenically transformed cells. Proc Natl Acad Sci USA 1995;92:381-5.
16. Lee SW, Reimer CL, Oh P, Campbell DB, Schnitzer JE. Tumor cell growth inhibition by caveolin re-expression in human breast cancer cells. Oncogene 1998;16:1391-7.
17. Fiucci G, Ravid D, Reich R, Liscovitch M. Caveolin-1 inhibits anchorage-independent growth, anoikis and invasiveness in MCF-7 human breast cancer cells. Oncogene 2002;21:2365-75.
18. Engelman JA, Wykoff CC, Yasuhara S, Song KS, Okamoto T, Lisanti MP. Recombinant expression of caveolin-1 in oncogenically transformed cells abrogates anchorage-independent growth. J Biol Chem 1997;272:16374-81.
19. Mouraviev V, Li L, Tahir SA, et al. The role of caveolin-1 in androgen insensitive prostate cancer. J Urol 2002;168:1589-96.
20. Suzuoki M, Miyamoto M, Kato K, et al. Impact of caveolin-1 expression on prognosis of pancreatic ductal adenocarcinoma. Br J Cancer 2002;87:1140-4.
21. Kato K, Hida Y, Miyamoto M, et al. Overexpression of caveolin-I in esophageal squamous cell carcinoma correlates with lymph node metastasis and pathologic stage. Cancer (Phila) 2002;94:929-33.
22. Ho CC, Huang PH, Huang HY, Chen YH, Yang PC, Hsu SM. Up-regulated caveolin-1 accentuates the metastasis capability of lung adenocarcinoma by inducing filopodia formation. Am J Pathol 2002;161:1647-56.
23. Yang G, Truong LD, Timme TL, et al. Elevated expression of caveolin is associated with prostate and breast cancer. Clin Cancer Res 1998;4:1873-80.
24. Nasu Y, Timme TL, Yang G, et al. Suppression of caveolin expression induces androgen sensitivity in metastatic androgen-insensitive mouse prostate cancer cells. Nat Med 1998;4:1062-4,
25. Yoo SH, Park YS, Kim HR, et al. Expression of caveolin-1 is associated with poor prognosis of patients with squamous cell carcinoma of the lung. Lung Cancer 2003;42:195-202.
26. Minna JD, Roth JA, Gazdar AF. Focus on lung cancer. Cancer Cell 2002;1:49-52.
27. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T. Duplexes of 21-nucteotide RNAs mediate RNA interference in cultured mammalian cells. Nature (Lond) 2001;411:494-8.
28. Borkhardt A. Blocking oncogenes in malignant cells by RNA interference-new hope for a highly specific cancer treatment? Cancer Cell 2002;2:167-8.
29. Sharp PA. RNA interferencen 2001. Genes Dev 2001;15:485-90.
30. Hannon GJ. RNA interference. Nature (Lond) 2002;418:244-51.
31. Caplen NJ, Parrish S, Imani F, Fire A, Morgan RA. Specific inhibition of gene expression by small double-stranded RNAs in invertebrate and vertebrate systems. Proc Natl Acad Sci USA 2001;98:9742-7.
32. Phelps RM, Johnson BE, Ihde DC, et al. NCI-Navy Medical Oncology Branch cell line data base. J Cell Biochem Suppl 1996;24:32-91.
33. Wistuba II, Bryant D, Behrens C, et al. Comparison of features of human lung cancer cell lines and their corresponding tumors. Clin Cancer Res 1999;5:991-1000.
34. Verma UN, Surabhi RM, Schmaltieg A, Becerra C, Gaynor RB. Small interfering RNAs directed against beta-catenin inhibit the in vitro and in vivo growth of colon cancer cells. Clin Cancer Res 2003;9:1291-300.
35. Braasch DA, Jensen S, Liu Y, et al. RNA interference in mammalian cells by chemically-modified RNA. Biochemistry 2003;42:7967-75.
36. Harada K, Toyooka S, Maitra A, et al. Aberrant promoter methylation and silencing of the RASSFIA gene in pediatric tumors and cell lines. Oncogene 2002;21:4345-9.
37. Xu XL, Wu LC, Du F, et al. Inactivation of human SRBC, located within the 11p15.5-p15.4 tumor suppressor region, in breast and lung cancers. Cancer Res 2001;61:7943-9.
38. Burbee DG, Forgacs E, Zochbauer-Muller S, et al. Epigenetic inactivation of RASSFIA in lung and breast cancers and malignant phenotype suppression. J Natl Cancer Inst (Bethesda) 2001;93:691-9.
39. Hayashi K, Matsuda S, Machida K, et al. Invasion activating caveolin-1 mutation in human scirrhous breast cancers. Cancer Res 2001;61:2361-4.
40. Wei Y, Yang X, Liu Q, Wilkins JA, Chapman HA. A role for caveolin and the urokinase receptor in integfin-mediated adhesion and signaling. J Cell Biol 1999:144:1285-94.
41. Engelman JA, Zhang XL, Lisanti MP. Sequence and detailed organization of the human caveolin-1 and -2 genes located near the D7S522 locus (7q31.1). Methylation of a CpG island in the 5′ promoter region of the caveolin-I gene in human breast cancer cell lines, FEBS Lett 1999;448:221-30.
42. Cui J, Rohr LR, Swanson G, Speights VO, Maxwell T, Brothman AR. Hypermethylation of the caveotin-1 gene promoter in prostate cancer. Prostate 2001;46:249-56.
43. Wary KK, Mariotti A, Zurzolo C, Giancotti FG. A requirement for caveotin-1 and associated kinase Fyn in integrin signaling and anchorage-dependent cell growth. Cell 1998;94:625-34.
44. Chien Y, White MA. RAL GTPases are linchpin modulators of human tumour-cell proliferation and survival. EMBO Rep 2003;4:800-6.
45. Baylin SB, Esteller M, Rountree MR, Bachman KE, Schuebel K, Herman JG. Aberrant patterns of DNA methylation, chromatin formation and gene expression in cancer. Hum Mol Genet 2001;10:687-92.
46. Zochbauer-Muller S, Fong KM, Virmani AK, Geradts J, Gazdar AF, Minna JD. Aberrant promoter methylation of multiple genes in non-small cell lung cancers. Cancer Res 2001;61:249-55.
47. Lee H, Park DS, Razani B, Russell RG, Pestell RG, Lisanti MP. Caveolin-1 mutations (P132L and null) and the pathogenesis of breast cancer: caveolin-1 (P132L) behaves in a dominant-negative manner and caveolin-1 (-/-) null mice show mammary epithelial cell hyperplasia. Am J Pathol 2002;161:1357-69.
48. Timme TL, Goltsov A, Tahir S, et al. Caveolin-1 is regulated by c-myc and suppresses c-myc-induced apoptosis. Oncogene 2000;19:3256-65.
49. Yang CP, Galbiati F, Volonte D, Horwitz SB, Lisanti MP. Upregulation of caveolin-1 and caveolae organelles in Taxol-resistant A549 cells. FEBS Lett 1998;439:368-72.
50. Lavie Y, Fiucci G, Liscovitch M. Upregulation of caveolin in multidrug resistant cancer cells: functional implications. Adv Drug Deliv Rev 2001;49:317-23.
51. Brummelkamp TR, Bemards R, Agami R. Stable suppression of tumorigenicity by virus-mediated RNA interference. Cancer Cell 2002;2:243-7.
52. Harborth J, Elbashir SM, Bechert K, Tuschl T, Weber K. Identification of essential genes in cultured mammalian cells using small interfering RNAs. J Cell Sci 2001;114:4557-65.
53. Crespo P, Leon J. Ras proteins in the control of the cell cycle and cell differentiation. Cell Mol Life Sci 2000;57:1613-36.
54. Aguirre-Ghiso JA, Frankel P, Farias EF, et al. RalA requirement for v-Src- and v-Ras-induced tumorigenicity and overproduction of urokinase-type plasminogen activator: involvement of metalloproteases. Oncogene 1999;18:4718-25.
55. Xu L, Frankel P, Jackson D, et al. Elevated phospholipase D activity in H-Ras- but not K-Ras-transformed cells by the synergistic action of RalA and ARF6. Mol Cell Biol 2003;23:645-54.
56. Suzuki M. Sunaga N, Shames DS, Toyooka S, Gazdar AF, Minna JD. RNA interference-mediated knockdown of DNA methyltransferase 1 leads to promoter demethylation and gene re-expression in human lung and breast cancer cells. Cancer Res 2004;64:3137-43.